MASTL/Aurora A-IN-1

MASTL/Aurora A-IN-1 (Compound MA4) is a dual inhibitor of MASTL and Aurora A kinases with IC50 values of 0.56 μM and 0.16 μM, respectively. MASTL/Aurora A-IN-1 has broad-spectrum anticancer activity and has potent anticancer activity against SR (leukemia), K-562 (leukemia), MDA-MB-435 (melanoma), MOLT-4 (leukemia), and SK-MEL-2 (melanoma) cell lines in NCI-60 cancer cell lines with GI50 values of 0.023, 0.032, 0.037, 0.044, and 0.051 μM, respectively. MASTL/Aurora A-IN-1 inhibits Aurora A and MASTL kinases, inducing cell cycle G2/M arrest, thereby inhibiting cancer cell proliferation. MASTL/Aurora A-IN-1 can be used in cancer research, especially for tumors with dysregulated mitosis[1].

321945-24-8

12352005

H302, H315, H319, H335

Aurora Kinase; MASTL; Ser/Thr Protease

Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; Metabolic Enzyme/Protease

Cancer-Kinase/protease

Cancer

99.47

DMSO : 116.67 mg/mL (ultrasonic)

O=C(NC1=C(C#N)C(CCCC2)=C2S1)CCC3=CC=CC=C3

C18H18N2OS

310.41

H302, H315, H319, H335

[1]Abdel-Rahman SA, Nada H, Gabr MT. First-in-class dual inhibitors of MASTL and Aurora A kinase: Discovery of selective cyclohexa[b]thiophenes with potent anticancer activity. Eur J Med Chem. 2025 May 8;293:117729.

Room Temperature

4°C (Powder, protect from light, stored under nitrogen)

http://file.medchemexpress.com/batch_PDF/HY-W231513/MASTL-Aurora-A-IN-1-SDS-MedChemExpress.pdf

Reference compound2

No Development Reported